Literature DB >> 19892045

Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome.

Nancy M Allen LaPointe1, Anita Y Chen, Matthew T Roe, David J Cohen, Deborah B Diercks, James W Hoekstra, Francis M Fesmire, W Brian Gibler, E Magnus Ohman, Eric D Peterson.   

Abstract

We evaluated the reported contraindications to early beta-blocker use and associated mortality within and across patient age groups. Contraindications to early beta-blocker use were evaluated in patients with non-ST-elevation acute coronary syndrome in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) initiative from February 2003 to December 2006. The prevalence, reasons, and trends in the contraindications were evaluated by age (<or=65, 66 to 74, and >or=75 years). The associations between the reported contraindications and in-hospital mortality were determined within and compared across age groups using the logistic generalized estimating equations method, adjusting for baseline patient characteristics. Of 112,448 patients, 11,711 (10.4%) had a reported contraindication to early beta-blocker use. The prevalence varied by age (<or=65, 7.9%; 66 to 74, 10.6%; and >or=75, 13.4%; p <0.0001). No significant changes were seen over time, except for a small increase in patients <or=65 years (p = 0.001). Among the hospitals with >40 patients in the registry, the median hospital level rate of reported contraindications was 9.9% (interquartile range 6.7% to 14.3%). The distribution of rates was more widespread among the hospitals' older versus younger patients. In all age groups, a statistically significant greater association was found with in-hospital mortality in those with reported contraindications versus those without contraindications who received a beta blocker (adjusted odds ratio 2.81, 95% confidence interval 2.28 to 3.46; adjusted odds ratio 2.50, 95% confidence interval 2.07 to 3.03; adjusted odds ratio 2.11, 95% confidence interval 1.88 to 2.37, for ages <or=65, 66 to 74, and >or=75 years, respectively). The strength of the association was similar across all age groups (interaction p = 0.19). The reported contraindications to early beta-blocker use were common and increased with age. The contraindications were independently associated with greater in-hospital mortality, underscoring the importance of accurately identifying contraindications. In conclusion, the results did not indicate any disparity in reporting the contraindications according to patient age.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19892045      PMCID: PMC2791368          DOI: 10.1016/j.amjcard.2009.06.054

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

1.  Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative.

Authors:  James W Hoekstra; Charles V Pollack; Matthew T Roe; Eric D Peterson; Ralph Brindis; Robert A Harrington; Robert H Christenson; Sidney C Smith; E Magnus Ohman; W Brian Gibler
Journal:  Acad Emerg Med       Date:  2002-11       Impact factor: 3.451

2.  Early beta-blocker therapy for acute myocardial infarction in elderly patients.

Authors:  H M Krumholz; M J Radford; Y Wang; J Chen; T A Marciniak
Journal:  Ann Intern Med       Date:  1999-11-02       Impact factor: 25.391

3.  Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

Authors:  Z M Chen; H C Pan; Y P Chen; R Peto; R Collins; L X Jiang; J X Xie; L S Liu
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

4.  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.

Authors: 
Journal:  N Engl J Med       Date:  1989-03-09       Impact factor: 91.245

5.  Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group.

Authors: 
Journal:  Eur Heart J       Date:  1985-03       Impact factor: 29.983

6.  ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine.

Authors:  Harlan M Krumholz; Jeffrey L Anderson; Brian L Bachelder; Francis M Fesmire; Stephan D Fihn; JoAnne M Foody; P Michael Ho; Mikhail N Kosiborod; Frederick A Masoudi; Brahmajee K Nallamothu
Journal:  J Am Coll Cardiol       Date:  2008-12-09       Impact factor: 24.094

7.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction).

Authors:  Elliott M. Antman; Daniel T. Anbe; Paul Wayne Armstrong; Eric R. Bates; Lee A. Green; Mary Hand; Judith S. Hochman; Harlan M. Krumholz; Frederick G. Kushner; Gervasio A. Lamas; Charles J. Mullany; Joseph P. Ornato; David L. Pearle; Michael A. Sloan; Sidney C. Smith; Joseph S. Alpert; Jeffrey L. Anderson; David P. Faxon; Valentin Fuster; Raymond J. Gibbons; Gabriel Gregoratos; Jonathan L. Halperin; Loren F. Hiratzka; Sharon Ann Hunt; Alice K. Jacobs; Joseph P. Ornato
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

8.  Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative.

Authors:  Adam H Skolnick; Karen P Alexander; Anita Y Chen; Matthew T Roe; Charles V Pollack; E Magnus Ohman; John S Rumsfeld; W Brian Gibler; Eric D Peterson; David J Cohen
Journal:  J Am Coll Cardiol       Date:  2007-04-16       Impact factor: 24.094

9.  Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.

Authors:  Karen P Alexander; L Kristin Newby; Paul W Armstrong; Christopher P Cannon; W Brian Gibler; Michael W Rich; Frans Van de Werf; Harvey D White; W Douglas Weaver; Mary D Naylor; Joel M Gore; Harlan M Krumholz; E Magnus Ohman
Journal:  Circulation       Date:  2007-05-15       Impact factor: 29.690

10.  Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: a multinational perspective.

Authors:  Robert J Goldberg; Frederick A Spencer; Philippe Gabriel Steg; Marcus Flather; Gilles Montalescot; Enrique P Gurfinkel; Brian M Kennelly; Shaun G Goodman; Rebecca Dedrick; Joel M Gore
Journal:  Arch Intern Med       Date:  2007-09-10
View more
  1 in total

1.  Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years.

Authors:  Kristian Kragholm; Sharif A Halim; Qinghong Yang; Phillip J Schulte; Judith S Hochman; Chiara Melloni; Kenneth W Mahaffey; David J Moliterno; Robert A Harrington; Harvey D White; Paul W Armstrong; E Magnus Ohman; Frans Van de Werf; Pierluigi Tricoci; John H Alexander; Robert P Giugliano; L Kristin Newby
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-07-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.